复康灵胶囊对乳腺癌多药耐药基因p170、GST-π影响的临床研究

目的:通过复康灵胶囊对新辅助化疗乳腺癌近期疗效以及对耐药基因p170、GST-π的调控研究,探索扶正解毒中药对化疗减毒增效的作用机制。方法:将53例需行新辅助化疗的乳腺癌患者分为治疗组与对照组,在进行相同方案化疗的基础上,治疗组在化疗开始时服用扶正解毒中药复康灵胶囊,对照组不服用。3周期化疗后观察2组乳腺实体肿瘤的改善情况,检测乳腺癌组织p170、GST-π的表达,并进行组间比较。结果:治疗组肿瘤完全缓解率为12.1%,部分缓解率为60.6%;对照组无完全缓解,部分缓解率为45%,2组比较具有显著性差异(P<0.05)。p170阳性率治疗组为12.1%,对照组为40%,2组比较具有显著性差异(P<0.05)。GST-π阳性率治疗组为36.4%,对照组为55%,2组比较无显著性差异(P>0.05)。结论:扶正解毒中药可以增强化疗效果,而调控耐药基因的表达是其作用机制之一。

Effects of Fukangling Capsule on Multidrug Resistant Geneprotein p170 and GST - π of Breast Cancer

OBJECTIVE： To observe the effect of Fukangling capsule on the short- term curative effect of neoadjuvant Chemotherapy for breast cancer and drug- resistant gene p170, GST- π, and to explore the mechanism of traditional Chinese medicine in decreasing the toxicity but increasing the curative effect of neoadjuvant chemotherapy. METHODS： 53 patients with breast cancer receiving neoadjuvant chemotherapy were divided into trial group and control group, The trial group received Fukangling capsule and chemotherapy concomitantly while the control group received chemotherapy alone. After receiving three cycles of chemotherapy, the improvement of breast tumor, the expression of p170 and GST-7 in breast tumor tissue were compared between the two groups. RESULTS. In the trial group, the complete remission rate（CR） was 12.1% and partial remission rate（PR） was 60.6%, versus 0 CR and 45% PR in the control group, and there were statistical differences between the two groups（P〈0.05）.The positive rate of p170 was 12.1% in the trial group versus 40% in the control group, and statistical difference had been found in two groups（P 〈 0.05） .The positive rate of GST - π was 36.4% in the trial group versus 55% in the control group, and no statistical difference had been found in two groups（P 〉0.05） .CONCLUSION .Traditional Chinese medicine with the function of strengthening the body resistance and detoxicating can increase the curative effect of chemotherapy, and one of the mechanisms is associated with its regulatory effect on the expression of drugresistant gene.